Fasting‑Mimicking Diet & Longevity: Dr. Valter Longo’s Findings

The world faces significant health challenges, with 60% of people in Europe and 75% in the United States being overweight or obese. Dr. Valter Longo, a leading researcher in longevity, fasting, and age-related diseases, believes that extending human healthspan and lifespan is achievable. His work, including the development of the fasting-mimicking diet (FMD), aims to address these issues by harnessing the body's natural regenerative capabilities.

The Impact of NIH Funding Freeze

Dr. Longo has voiced concerns regarding the recent freeze on NIH grant review panels, emphasizing its potential repercussions for critical research. The NIH allocates approximately $47 billion, funding not only fundamental science but also clinical trials, particularly for diseases that may not be profitable for pharmaceutical companies, such as rare diseases. Interruptions in this funding can impede progress in developing new treatments and cures.

Fasting and Longevity: Latest Insights

Dr. Longo's research explores various fasting protocols and their health effects.

Time-Restricted Eating (TRE)

He advocates for a 12-hour daily fasting window (12 hours of eating, 12 hours of fasting) as the safest and most effective approach for the general population. While a 16-hour fasting window might offer additional benefits, the 12-hour window is easier to maintain and has no known negative side effects. This recommendation is supported by epidemiological data, clinical trials, and the dietary habits of centenarians.

The average person currently eats for approximately 15 hours a day. Reducing this to 12 hours can lead to:

• Reduced calorie intake: Fewer opportunities to eat naturally result in lower calorie consumption.
• Metabolic switches: Encourages the body to transition from fat-storing to fat-burning mode.
• Improved sleep: Studies indicate that reducing the eating window can enhance sleep quality.

Dr. Longo advises against eating for the last three hours before sleep, though he acknowledges individual variations in response.

Fasting-Mimicking Diet (FMD)

The FMD is a plant-based, low-calorie, low-sugar, low-protein, high plant-based fat program designed to physiologically mimic the effects of water-only fasting. It was developed to achieve the benefits of calorie restriction without the difficulties of long-term adherence. The FMD is typically followed for five days, either once a month or every three to four months.

The FMD operates by:

• Triggering a fasting response: The diet is formulated to activate the same biological pathways as water-only fasting, as measured by specific blood markers.
• Promoting regeneration: It activates the body's inherent regenerative and developmental programs, including cellular reprogramming and stem cell activation. This has been observed in studies on kidney damage in rats and in human clinical trials.
• Metabolic switching: It shifts the body from a fat-storing mode to a fat-burning mode without inducing a "thrifty mode," where the body conserves energy due to perceived starvation.

The Longevity Diet

Beyond fasting, Dr. Longo's work also focuses on the "longevity diet," a pescetarian diet that emphasizes plant-based foods and low but sufficient protein. This diet is currently being compared to vegan and ketogenic diets in ongoing research to understand its impact on aging, longevity, age-related diseases, frailty, and strength.

Key aspects of the longevity diet and its protective mechanisms include:

• Amino acid profiles: Dr. Longo argues that focusing on protein levels is less important than understanding the amino acid profiles of different protein sources. Plant-based proteins can have vastly different amino acid compositions compared to animal-based proteins.
• Genetic regulation of aging: The diet influences genes that regulate the aging process, such as IGF-1, growth hormone, and mTOR. Manipulating these genes in simple organisms has shown significant lifespan extension.
• Personalization: The ideal diet needs to be personalized, as individual responses to foods can vary significantly (e.g., eggplant causing inflammation in some individuals).

Disease Reversal and Treatment

Dr. Longo's research has shown promising results in disease reversal, particularly with the FMD.

Diabetes

Clinical trials have demonstrated a 50-70% regression of type 2 diabetes with FMD cycles, even without changes to daily diet or lifestyle. This suggests that the FMD can standardize a "food as medicine" approach to cure diseases. Studies have shown impressive reductions in A1C levels and drug use.

Kidney Disease

Research on rats with kidney damage showed that FMD cycles could completely reverse gene expression disruption and restore kidney architecture. In a small human trial, FMD cycles reduced proteinuria (a marker of kidney damage), and this benefit was maintained a year later. Patients also showed a threefold increase in kidney progenitor cells in their blood, suggesting a regenerative process.

Cancer

The FMD, in conjunction with traditional cancer treatments, appears to have a beneficial impact on recovery and remission rates. Animal studies have shown that FMD can significantly enhance the effectiveness of chemotherapy, immunotherapy, and hormone therapy, leading to tumor regression and increased survival.

For advanced-stage cancers (stage three or four), FMD has shown significant benefits, nearly doubling overall survival in some studies (e.g., triple-negative breast cancer). However, for early-stage cancers with high cure rates from traditional treatments, Dr. Longo advises caution and sticking to standard care, as the long-term effects of FMD in these specific contexts are still being studied.

The Role of Protein in Longevity

Dr. Longo challenges the common emphasis on high protein intake, particularly from animal sources.

• FMD and muscle mass: The FMD, despite being low in protein, has been clinically shown to increase muscle mass after multiple cycles, not decrease it.
• Epidemiological data: Studies, including those published in JAMA, indicate that low but sufficient protein intake, especially plant-based, is associated with better health outcomes and lower mortality up to age 65. After 65, a slightly higher protein intake may be beneficial to counteract age-related muscle loss.
• Animal studies: Decades of research in mice and rats consistently show that low protein, low methionine diets lead to longer lifespans.
• Centenarian diets: Historical diets of centenarian populations, like Okinawans, were typically low in protein (around 9%).
• Growth factors and aging: High protein intake drives growth factors (like IGF-1), which are central to the aging process. Studies on individuals with growth hormone receptor deficiency (e.g., Laron syndrome in Ecuador) show protection from diabetes, cancer, and cognitive decline, despite often having poor diets.
• Diabetes risk: Harvard studies have shown a 40% increased risk of diabetes in subjects consuming high-protein diets compared to those with the lowest intake.

Dr. Longo emphasizes that the focus should be on amino acid profiles rather than just total protein. A balanced intake of essential amino acids, particularly from diverse plant sources (legumes, seeds, nuts), is crucial. He suggests that for active individuals, around 30 grams of high-quality protein per meal (twice a day) is sufficient to maximize muscle building without overstimulating pro-aging pathways.

The "Effort" in Health

Dr. Longo stresses the importance of effort and discipline in achieving long-term health. He draws parallels to the adoption of regular exercise, which took decades to become mainstream. While some individuals may benefit from pharmaceutical interventions like GLP-1 agonists (e.g., Ozempic), he advocates for a comprehensive, personalized approach involving dietitians, molecular biologists, and physicians. This approach, exemplified by the Create Cures Foundation, focuses on gradual, sustainable lifestyle changes over one to two years, minimizing drastic shifts to avoid the "yo-yo" effect.

Caution Against Extreme Protocols

Dr. Longo expresses skepticism about highly restrictive or complex protocols, such as those involving numerous supplements or extremely narrow eating windows (like Brian Johnson's Blueprint protocol). He warns that while short-term benefits might be observed, the long-term effects are often unknown and could be detrimental. The complexity of interactions between multiple supplements and their impact on the body's metabolism can lead to unforeseen problems, potentially years down the line. He highlights that even common prescription drugs cause tens of thousands of deaths annually due to interactions, underscoring the risks of unproven combinations.

He also cautions against misinterpreting data, such as the idea that extremely low body fat is always healthier. Longevity data often suggests that a slightly higher BMI (around 25) may be associated with longer lifespans.

Ultimately, Dr. Longo advocates for a balanced, evidence-based approach rooted in the "five pillars" of longevity research: epidemiology, clinical studies, basic research (animal models), centenarian studies, and complex systems analysis. This comprehensive perspective helps to avoid pitfalls and ensure that interventions promote health and longevity without creating new problems.

Fasting Mimicking Diet and Cancer Treatment: A Detailed Look

The Fasting Mimicking Diet (FMD) shows significant promise, particularly for advanced-stage cancers (stage three and four). Clinical studies indicate that FMD can enhance the effectiveness of conventional treatments like chemotherapy.

Impact on Triple-Negative Breast Cancer

One notable example is triple-negative breast cancer, an aggressive form of metastatic cancer. Studies by Verdin and colleagues have demonstrated that FMD nearly doubles overall survival rates. A follow-up paper further explored this, comparing chemotherapy alone, chemotherapy plus FMD, and chemotherapy plus FMD and metformin. The results consistently showed nearly a doubling of complete pathological response (PCR) compared to expected survival rates. These are just a few examples, but numerous trials suggest FMD improves both survival and pathological response, leading to fewer active cancer cells in tumor masses after treatment.

Cautions and Considerations

While promising, it's crucial to use FMD carefully. Misusing it, such as refeeding during chemotherapy, can cause problems. FMD also has a powerful effect on stem cells. While it has been shown to reduce cancer stem cells in breast cancer, some research suggests it could increase them in certain early-stage cases.

For early-stage cancers with a high cure rate (e.g., 98%), it's generally recommended to stick to standard treatment. In such cases, incorporating a longevity diet or time-restricted eating (e.g., 12-hour eating window) might be beneficial, but FMD should be approached with caution due to potential unknown effects. The decision to use FMD should be case-dependent, considering the type and advancement of the cancer.

Animal Studies and Broader Applications

Animal studies overwhelmingly support the benefits of FMD across various cancers, including colorectal, lung, and breast cancer. FMD combined with chemotherapy, immunotherapy, hormone therapy, or kinase inhibitors has shown phenomenal effects, even turning around cancers that were previously resistant to treatment. For instance, in mice, FMD cycles combined with standard hormone therapy (Palbociclib and Fulvestrant) led to tumor regression to zero, whereas standard therapy alone only kept the tumor in check for a period before it adapted and grew.

Remarkably, in some mouse models of breast cancer and melanoma, FMD alone has shown more efficacy than immunotherapy. This highlights the immense potential of FMD across different cancer types and stages. However, due to the complexity of biological systems and the need for more clinical data, a cautious approach is warranted.

Clinical Application and Oncologist Involvement

For stage four cancer patients where other treatments are failing, FMD is a strong consideration, given the compelling animal data. However, for stage one patients with effective existing treatments, it's advisable to stick to the standard of care.

Clinical trials, particularly for triple-negative breast cancer and hormone therapy, are starting to show significant differences in randomized trials. Patients are encouraged to discuss these findings with their oncologists.

The level of awareness among oncologists regarding FMD varies. Many may wait for FDA approval, which is a complex and expensive process for FMD due to its multi-ingredient nature. The current approach involves standardizing the diet and accumulating sufficient trial data to encourage oncologists to recommend it.

Breast Cancer: A Focus Area in Human Trials

While animal studies show FMD's effectiveness across many cancers, human trials have focused more on breast cancer. This is partly due to a better understanding of the disease and more clinical effort dedicated to it. However, trials are now expanding to other cancers like colorectal and prostate cancer.

A randomized study involving 131 breast cancer patients showed promising results. Patients who combined FMD with chemotherapy had significantly higher rates of tumor-free masses:

• 8% for chemotherapy alone.
• 29% with one cycle of FMD.
• 33% with three or four cycles of FMD.
• 53% with FMD combined with all chemotherapy cycles.

While these results are significant, particularly for metastatic cancer, caution is advised for early-stage breast cancer patients in this specific trial, as it was conducted before surgery and long-term survival data is still needed. The concern about cancer stem cells and other potential effects in early stages remains.

For metastatic cancer, where overall survival differences are observed in early trials, FMD is a more optimistic and exciting prospect. It's considered a "wild card" for cancer patients whose current treatments are not working, after careful discussion with their oncologist.

The "Starvation Escape Pathway Blockade"

Cancer cells are often described as "food-stealing thieves" that thrive on abundant nutrients. Normal cells, having evolved over billions of years, are adept at surviving starvation. FMD aims to starve cancer cells, which are less adaptable to nutrient deprivation.

When FMD is combined with conventional therapies, it can drive cancer down to zero or halt its progression for extended periods. Researchers are developing a technology called "starvation escape pathway blockade." This involves using RNA-seq technology to identify how cancer cells rewire themselves in response to FMD. By understanding these "escape pathways," specific drugs (often already FDA-approved) can be used to block them, effectively trapping and eliminating the cancer cells. This approach has shown incredible effects in animal models, leading to sustained tumor regression.

The Book's Message and Target Audience

The book aims to convey a message of caution and informed decision-making. It's not a panacea but rather a presentation of current research and future directions.

The book is for:

• Cancer prevention: Emphasizing the role of FMD, longevity diet, and time-restricted eating in preventing cancer by addressing aging.
• Early-stage cancer patients: Recommending the longevity diet and time-restricted eating, along with other healthy practices, if side effects are low and treatment is smooth.
• Metastatic cancer patients or those with failing treatments: Suggesting FMD as a potential option, in consultation with an oncologist.

The Role of AI in Cancer Treatment

AI is expected to revolutionize cancer treatment, particularly in identifying escape pathways and suitable drugs. Within two to three years, with sufficient funding, AI could rapidly pinpoint these pathways, allowing for the use of existing FDA-approved drugs to block them. This could lead to "cancer antibiotics" – low-toxicity treatments that target cancer effectively. While the timeline is uncertain, with proper funding, this could become a reality within 10 years.

AI Beyond Cancer: A Broader Perspective

The speaker expresses significant apprehension about AI's broader societal impact, viewing it as a system that can evolve and learn, potentially leading to unforeseen and negative consequences for humanity. The analogy of evolution is used, suggesting that just as biological systems evolve, AI systems will also find their own way, and this path might not align with human interests.

The current focus on financial gain in AI development is seen as a driving force behind an "irrational exuberance" that overlooks potential worst-case scenarios. The speaker advocates for global regulation of AI, similar to how nuclear power was approached, to mitigate potential risks. The comparison to nuclear power highlights the potential for catastrophic outcomes if AI is not carefully managed. While acknowledging the short-term benefits of AI, particularly in healthcare, the speaker emphasizes the lack of humility in addressing the profound existential questions and potential dangers it poses.